MannKind reported $-3.05M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Adma Biologics USD 61.07M 12.52M Mar/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Insmed USD -148.3M 165.88M Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -30.2M 52.15M Mar/2026
MannKind USD -3.05M 20.97M Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Novavax USD 19.36M 190.79M Dec/2025
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Pfizer USD 5.99B 5.23B Mar/2026
Sanofi EUR 3.31B 3.65B Mar/2026
Xencor USD -51.05M 55.28M Dec/2025